US EditionBioMarin Pharmaceutical (NASDAQ:BMRN) Cut to “Buy” at StockNews.com
Summary by modernreaders.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
BioMarin Pharmaceutical (NASDAQ:BMRN) Cut to “Buy” at StockNews.com
StockNews.com cut shares of BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) from a strong-buy rating to a buy rating in a report released on Thursday. BMRN has been the topic of several other reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $90.00 target price on shares of BioMarin Pharmaceutical in a research note on Thursday, February 20th. UBS Group increased their price objective on BioMarin Pharmaceutical from $109…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
